43 patents
Utility
Crystalline Substituted Pyrazines As PGI2 Receptor Agonists
28 Sep 23
Toshio FUJIWARA
Filed: 12 Apr 23
Utility
Crystals
10 Aug 23
A main object of the present invention is to provide new crystals of (S)-N2-[1-(4-fluorophenyl)ethyl]-4-(1-methyl-1H-pyrazol-4-yl)-N6-(pyrazin-2-yl)pyridine-2,6-diamine maleate (hereinafter, referred to as “compound A”).
Toshio FUJIWARA, Joanna BIS, Senthil Kumar Kusalakumari SUKUMAR
Filed: 13 Apr 23
Utility
Antisense Nucleic Acids
18 May 23
The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene.
Naoki Watanabe, Youhei Satou, Shin'ichi Takeda, Tetsuya Nagata
Filed: 8 Nov 22
Utility
Antisense Nucleic Acid Inducing Skipping of Exon 51
4 May 23
The present specification provides a drug that causes highly-efficient skipping of exon 51 in the human dystrophin gene.
Yu HONDA, Kaname MUCHIMA, Takahiro FUKUI, Saki HASEGAWA, Shin'ichi TAKEDA, Yoshitsugu AOKI
Filed: 26 Feb 21
Utility
Prophylactic And/or Therapeutic Agent for Chronic Prostatitis/chronic Pelvic Pain Syndrome
30 Mar 23
The present invention relates to a prophylactic and/or therapeutic agent for chronic prostatitis/chronic pelvic pain syndrome, the agent containing an mPGES-1 inhibitor as an active ingredient.
Ken OKAMOTO, Maki KURITA, Hiroshi YAMAGUCHI
Filed: 24 Dec 20
Utility
Compound and Composition As PDGF Receptor Kinase Inhibitor
30 Mar 23
Junshi ASADA, Yoshinari HARUTA, Hiroyuki YAKUSHIJI, Toru TANAKA, Kazuya KURAMOTO, Keiji KOSUGI, Chiaki FUCHIKAMI
Filed: 11 Dec 20
Utility
Antisense Nucleic Acid Inducing Skipping of Exon 51
30 Mar 23
The present specification provides a drug that causes highly-efficient skipping of exon 51 in the human dystrophin gene.
Yu HONDA, Kaname MUCHIMA, Takahiro FUKUI, Saki HASEGAWA, Shin'ichi TAKEDA, Yoshitsugu AOKI
Filed: 25 Aug 22
Utility
Antisense Nucleic Acid That Induces Skipping of Exon 50
9 Mar 23
The present specification provides a drug that causes highly-efficient skipping of exon 50 in the human dystrophin gene.
Yukiko ENYA, Yuta SUNADOI, Reiko WAKI, Kaname MUCHIMA, Shin'ichi TAKEDA, Yoshitsugu AOKI
Filed: 25 Dec 20
Utility
Antitumor Drug for Use In Combination with Immune Checkpoint Inhibitor
9 Feb 23
The present invention relates to a prophylactic and/or therapeutic agent for cancer containing an mPGES-1 inhibitor as an active ingredient, the agent being useful in combination with an immune checkpoint inhibitor, and the invention has industrial applicability.
Keiji KOSUGI, Toshiyuki MINAMI, Shiho IWASAKI, Itaru YAMAMOTO
Filed: 24 Dec 20
Utility
Antisense Nucleic Acid Enabling Exon Skipping
9 Feb 23
The present specification provides an antisense oligomer capable of causing simultaneous skipping of a plurality of exons in pre-mRNA of interest, and a pharmaceutical composition comprising the oligomer.
Naoki WATANABE, Yuichiro TONE, Shin'ichi TAKEDA, Yoshitsugu AOKI
Filed: 18 Dec 20
Utility
Method for Producing Oligonucleic Acid Compound
19 Jan 23
The present invention relates to a method for producing a compound represented by general formula [C-1-1], which comprises: a step for reacting a compound represented by general formula [B-1-1] with a compound represented by general formula [P] to form a compound represented by general formula [B-1-2]; and a step for reacting the compound represented by general formula [B-1-2] with a compound represented by general formula [A-1] to form the compound represented by general formula [C-1-1].
Yutaro KOTOBUKI, Koki KATO
Filed: 13 Nov 20
Utility
Method for Producing Oligonucleic Acid Compound
19 Jan 23
The present invention relates to a method for producing a compound [C] of the general formula [C] by subjecting a compound [A] having a hydroxyl group or a primary or secondary amino group and a compound [B] having a phosphorous atom-containing substituent group of the general formula [1] to a condensation reaction, characterized in that the method is carried out in the presence of at least one reaction accelerator selected from the group consisting of a quaternary ammonium salt, a quaternary imidazolium salt, a quaternary morpholinium salt, a quaternary phosphonium salt, a quaternary piperidinium salt, a quaternary pyridinium salt, a quaternary pyrrolidinium salt and a quaternary sulfonium salt.
Junshi ASADA
Filed: 13 Nov 20
Utility
Therapeutic Agents and Prophylactic Agents for Functional Gastrointestinal Disorders and Xerostomia
5 Jan 23
Ryohei YOSHINAGA, Maki KURITA, Yasunori ASAO, Tomomi FUKUI
Filed: 12 Nov 20
Utility
Azabenzimidazole Compound and Medicine
5 Jan 23
Koya OIKAWA, Takuto YAMANAKA, Sho HIRAI, Kazuhiko WAKITA
Filed: 12 Nov 20
Utility
Antisense Nucleic Acid That Induces Skipping of Exon 50
20 Oct 22
The present specification provides a drug that causes highly-efficient skipping of exon 50 in the human dystrophin gene.
Yukiko ENYA, Yuta SUNADOI, Reiko WAKI, Kaname MUCHIMA, Shin'ichi TAKEDA, Yoshitsugu AOKI
Filed: 23 Jun 22
Utility
Salt
8 Sep 22
The present invention relates to a novel salt of 2-(4-(5,6-diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)acetic acid (hereinafter referred to as “Compound B”) and a crystal of the salt thereof.
Yasushi KOKUBO, Toshitaka YAMAMOTO, Koji NAKAMICHI, Domenico CROCCO
Filed: 19 Aug 20
Utility
Measuring Container, Loading Tool, and Measuring Container Kit
21 Jul 22
A measuring container comprises a storage container and a storage section selector.
Masaki HAYAKAWA
Filed: 8 Apr 20
Utility
Antisense Nucleic Acids
26 May 22
Provided is a drug that allows highly-efficient skipping of exon 51 in the human dystrophin gene.
Tatsushi WAKAYAMA, Haruna SEO, Youhei SATOU, Shin'ichi TAKEDA, Tetsuya NAGATA
Filed: 30 Jun 21
Utility
Method for Inducing Muscular Cells Using Cells In Spot Urine
12 May 22
A method for preparing myotubes in a non-invasive and simple manner and establishes an in vitro test system of an agent used for exon skipping therapy for muscular dystrophy.
Hotake TAKIZAWA, Yoshitsugu AOKI, Shin'ichi TAKEDA, Yukiko ENYA, Yuichiro TONE
Filed: 25 Dec 18
Utility
Myostatin Signal Inhibitor
21 Apr 22
The present invention provides a new approach for inhibiting myostatin signaling by targeting ACVR2B at the mRNA level.
Shinichiro NAKAGAWA
Filed: 26 Dec 19